Search

everythinglearnresearchcommunity

for

Search:↓

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

User reports regrowth at temples and improved hairline density after 6 months of using 0.5 mg Dutasteride daily, topical minoxidil twice daily, and vitamins. Considering adding copper peptide but concerned about overdoing it; experiencing increased shedding on the crown.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

Vitamin D may counteract DHT and help with hair growth, as seen in mice and human hair cultures. Some users discuss using Vitamin D, magnesium, and other supplements for hair health, while others humorously note the success in mice.

A user shared their aggressive hair loss treatment regimen, which includes daily use of Avodart (dutasteride) and Minoxidil, bi-weekly use of Davines Purifying shampoo, and almost daily use of Ducray Anaphase+ shampoo, along with supplements like vitamin D3, collagen, biotin, and zinc. They also use a dermastamp every 10 days and are considering a hair transplant for increased density, followed by a switch to finasteride and Minoxidil foam.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

A sugar gel containing 2-deoxy-D-ribose has shown promising hair regrowth results in mice, comparable to Minoxidil. Users are discussing the potential to buy and try this compound themselves.

Dutasteride and finasteride are not effectively stopping hair loss for some users, despite long-term use. Some are considering or using RU58841, pyrilutamide, and other treatments like microneedling, while also managing seborrheic dermatitis with diet and topical solutions.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

The conversation discusses using microneedling with growth factor serum, PRF injections, dutasteride, oral and topical minoxidil, and topical exosomes to treat hair loss, particularly on the crown. OP plans to microneedle twice a month and seeks feedback on Korean growth factor serums.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

The user "ajsr8" shared their story of hair loss despite being on treatments. They started using finasteride in 2019 and later tried topical minoxidil, but it didn't seem to work. They also experienced side effects from other treatments. They are considering cutting off their hair and stopping the medications if there is no improvement in three months. Other users suggested trying different treatments and getting a blood test to check for underlying conditions.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.

A user shared their 3-month progress using RU58841, 10% minoxidil, and microneedling every two weeks for hair loss. They found the new minoxidil sprayer effective for applying the treatment across the scalp.

Tazarotene shows potential as a standalone treatment for hair regrowth by stimulating new hair follicle formation and promoting angiogenesis, similar to microneedling effects. It can be used topically without minoxidil, but users should start with a low concentration to avoid irritation.

A user's 61-year-old father regained a full head of hair after four years on dutasteride for his prostate and five months of weight loss and exercise. The user decided to switch from finasteride to dutasteride and continue exercising, inspired by his father's results.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

The user experienced hair loss starting at 16 and used finasteride and minoxidil, later switching to dutasteride and oral minoxidil, which improved hair thickness after an initial shedding phase. The user also noted the importance of using shampoo to manage dermatitis and maintain scalp health.

A 49-year-old is updating on hair regrowth progress using finasteride, minoxidil foam, tretinoin cream, and ketoconazole shampoo. They report thicker, darker hair and reduced scalp itch after switching to minoxidil foam.

User maintained hair with finasteride for 6 months, then switched to dutasteride for 7 months, using DHT blocking shampoo, keto 2% shampoo, and microneedling. Significant hair growth observed, especially on right temple.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.